Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.49 |
| ▸ | SLC6A9 | P48067 | 7/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6629281 | 0.82 | PDE5A (0.41) | PDE5ASLC6A9KCNH2KDM4EMAPT | |
| SCHEMBL6202135 | 0.81 | PDE5A (0.45) | PDE5AKDM4EMAPTKDM4C | |
| SCHEMBL6810231 | 0.80 | PDE5A (0.48) | PDE5ASLC6A9GPR119KCNH2LRRK2 | |
| SCHEMBL6805629 | 0.79 | PDE5A (0.42) | PDE5ASLC6A9KCNH2GPR55KDM4E | |
| SCHEMBL6802097 | 0.77 | PDE5A (0.36) | PDE5ASLC6A9KCNH2 | |
| SCHEMBL6807069 | 0.77 | PDE5A (0.37) | PDE5ASLC6A9KCNH2DHODH | |
| SCHEMBL6803597 | 0.76 | PDE5A (0.36) | PDE5ASLC6A9KCNH2LRRK2 | |
| SCHEMBL6806895 | 0.75 | SLC6A9 (0.38) | PDE5ASLC6A9GPR119KCNH2GPR55 | |
| SCHEMBL6777523 | 0.74 | PDE5A (0.58) | PDE5AMAPT | |
| SCHEMBL6810517 | 0.74 | PDE5A (0.40) | PDE5ASLC6A9GPR119KCNH2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368352-B1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | PFIZER LTD (GB) | 2004-12-01 | — | — | EP | disclosed |
| US-6770645-B2 | SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS | PFIZER INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030064990-A1 | Pharmaceutically active compounds | PFIZER INC. | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064990-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | PDE5A 1/4885SLC6A9 3970/4885GPR119 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.